NIKKEI 225
38,714.56 +224.39 (+0.58%) HANG SENG
18,533.22 +108.26 (+0.59%) CRUDE OIL
74.48 +0.41 (+0.55%) GOLD FUTURES
2,387.30 +11.80 (+0.50%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,461.59 -44.26 (-0.08%)
CytomX Therapeutics, Inc. (6C1.F)
| Previous close | 1.6700 |
| Open | 1.5030 |
| Bid | 1.5060 x 200000 |
| Ask | 1.5930 x 200000 |
| Day's range | 1.5030 - 1.5030 |
| 52-week range | 0.9760 - 4.4020 |
| Volume | |
| Avg. volume | 840 |
| Market cap | 117.113M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | 7.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. I
- GlobeNewswire
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. The stock options were granted pursuant to the Company’s 201
- GlobeNewswire
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pe
